RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenes
Leona A. Martin, G.G. Li, Annelie Schairer, Aleksandra Franovic(Ondine Biopharma (United States)), Pratik S. Multani(Ignyta (United States)), Declan Murphy(King's College London), Jesuchristopher Joseph, Jason Christiansen, Amy Diliberto, Christine M. Walsh(University of Calgary), Ravi B. Patel, Sean Uryu(Pfizer (United States)), E. Kowack, R. H. Shoemaker, Jamie R. Oliver(University of Kansas Medical Center)
Cited by 0
Related Papers
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy
|Nature Reviews Drug Discovery|2012|1.3k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Neuroimaging in autism spectrum disorder: brain structure and function across the lifespan
|The Lancet Neurology|2015|518